Antidiabetic Potential of Ruthenium(III) Hydroxamate Complexes:
Spectrophotometric Investigations

Raj      Kaushal; Mandeep      Kaur

doi:10.2174/1573408018666220825152849

Abstract

Background: The potential antidiabetic and antioxidant properties of four ruthenium(III) hydroxamate complexes [RuCl(H₂O)(L^I-III)₂] (1-3) and [RuCl₃(H₂O)(HL^IV)₂] (4) were investigated on α- cell enzymes (α-amylase and α-glucosidase).

Methods: In the instance of α-amylase inhibition investigations, the antidiabetic studies of the complexes revealed that they are more active than even the Acarbose as standard, with complex 4 having an IC₅₀ value of 52.31 g/ml. For α-glucosidase inhibition, complex 4 was observed to be the best inhibitor with a remarkable 0.35μg/ml IC₅₀ value, which may be attributed to the size and superior lipophilicity of this complex, enabling it to interact with the biological system more effectively than complexes 1-3. The complexes with the best IC₅₀ values were studied further for enzyme kinetics. Molecular docking studies were performed as well to investigate the interactions between the synthesized complexes and target enzymes viz., α-glucosidase and α-amylase.

Results: The obtained in-vitro results have also been supported by the results of the in-silico docking studies. Furthermore, the antiradical activity of Ru(III) complexes was assessed for its effectiveness in reducing oxidative stress.

Conclusion: All the complexes (except complex 3) exhibited remarkable antiradical activity.

Keywords: α-amylase inhibition, Analytical Methods, Antioxidants, Docking studies, α-glucosidase inhibition, Kinetics, Ruthenium(III)hydroxamate complexes.

« Previous Next »

Graphical Abstract

[1]
a) Kerru N, Singh-Pillay A, Awolade P, Singh P. Current anti-diabetic agents and their molecular targets: A review. Eur J Med Chem  2020; 152: 436-88. http://dx.doi.org/10.1016/j.ejmech.2018.04.061; 
b) Paudel S, Tran T, Owen AJ, Smith BJ. The contribution of physical inactivity and socioeconomic factors to type 2 diabetes in Nepal: a structural equation modelling analysis. Nutr Metab Cardiovasc Dis  2020; 30(10): 1758-67. http://dx.doi.org/10.1016/j.numecd.2020.06.003

[2]
Rice BBH. Dietary fat and risk for type 2 diabetes: A review of recent research. Curr Nutr Rep  2018; 7(4): 214-26.
 [http://dx.doi.org/10.1007/s13668-018-0244-z] [PMID:  30242725]

[3]
Bishu KG, Jenkins C, Yebyo HG, Atsbha M, Wubayehu T, Gebregziabher M. Diabetes in ethiopia: A systematic review of prevalence, risk factors, complications, and cost. Obes Med  2019; 15(100132): 100132.
 [http://dx.doi.org/10.1016/j.obmed.2019.100132]

[4]
Ceriello A, deValk HW, Guerci B. et al. The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives. Diabetes Res Clin Pract  2020; 161(7): 108053.
 [http://dx.doi.org/10.1016/j.diabres.2020.108053] [PMID:  32035117]

[5]
W.H. Organization. Diabetes. 2020. Available from: https://www.who.int/news-room/factsheets/detail/diabetes

[6]
Suwannaphant K, Laohasiriwong W, Puttanapong N, Saengsuwan J, Phajan T. Association between socioeconomic status and diabetes mellitus: The national socioeconomics survey, 2010 and 2012. J Clin Diagn Res  2017; 11(7): LC18-22.
 [http://dx.doi.org/10.7860/JCDR/2017/28221.10286] [PMID:  28892937]

[7]
Mutyambizi C, Booysen F, Stokes A, Pavlova M, Groot W. Lifestyle and socio-economic inequalities in diabetes prevalence in South Africa: A decomposition analysis. PLoS One  2019; 14(1): e0211208.
 [http://dx.doi.org/10.1371/journal.pone.0211208] [PMID:  30699173]

[8]
Peng M, Yang X. Controlling diabetes by chromium complexes: The role of the ligands. J Inorg Biochem  2015; 146: 97-103.
 [http://dx.doi.org/10.1016/j.jinorgbio.2015.01.002] [PMID:  25631328]

[9]
Maikoo S, Makayane D, Booysen IN, Ngubane P, Khathi A. Ruthenium compounds as potential therapeutic agents for type 2 diabetes mellitus. Eur J Med Chem  2021; 213(113064): 113064.
 [http://dx.doi.org/10.1016/j.ejmech.2020.113064] [PMID:  33279292]

[10]
Weigelt B, Peterse JL, Van ’t Veer LJ. Breast cancer metastasis: Markers and models. Nat Rev Cancer  2005; 5(8): 591-602.
 [http://dx.doi.org/10.1038/nrc1670] [PMID:  16056258]

[11]
Javid MT, Rahim F, Taha M. et al. Synthesis, in vitro α-glucosidase inhibitory potential and molecular docking study of thiadiazole ana-logs. Bioorg Chem  2018; 78: 201-9.
 [http://dx.doi.org/10.1016/j.bioorg.2018.03.022] [PMID:  29597114]

[12]
Swaroopa V, Reddy VJS, Koshma M, Sudharani Y, Basha SJ, Adithya TN. Review on antidiabetic activity on medicinal plants. Int J Phar-macol Res  2017; 7: 230-5.
 [http://dx.doi.org/10.7439/ijpr.v7i12.4457]

[13]
Leung CH, Zhong HJ, Chan DSH, Ma DL. Bioactive iridium and rhodium complexes as therapeutic agents. Coord Chem Rev  2013; 257(11–12): 1764-76.
 [http://dx.doi.org/10.1016/j.ccr.2013.01.034]

[14]
Gitlin JD, Lill R. Special issue: Cell biology of metals. Biochim Biophys Acta Mol Cell Res  2012; 1823(9): 1405.
 [http://dx.doi.org/10.1016/j.bbamcr.2012.07.008]

[15]
Howerton BS, Heidary DK, Glazer EC. Strained ruthenium complexes are potent light-activated anticancer agents. J Am Chem Soc  2012; 134(20): 8324-7.
 [http://dx.doi.org/10.1021/ja3009677] [PMID:  22553960]

[16]
Frezza M, Hindo S, Chen D. et al. Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des  2010; 16(16): 1813-25.
 [http://dx.doi.org/10.2174/138161210791209009] [PMID:  20337575]

[17]
Yang Y, Liao G, Fu C. Recent advances on octahedral polypyridyl ruthenium(II) complexes as antimicrobial agents. Polymers (Basel)  2018; 10(6): 650.
 [http://dx.doi.org/10.3390/polym10060650] [PMID:  30966684]

[18]
Wabaidur SM, Eldesoky GE, Alothman ZA. The fluorescence quenching of Ru(bipy)32+: An application for the determination of biliru-bin in biological samples. Luminescence  2018; 33(3): 625-9.
 [http://dx.doi.org/10.1002/bio.3455] [PMID:  29399944]

[19]
Lee SH, Jeon CW, Wabaidur SM. Flow-injection chemiluminescence determination of aspartic acid in tea leaves using tris (2,2′-bipyridyl) ruthenium (II)-Ce(IV) system. J Fluoresc  2008; 18(3-4): 655-60.
 [http://dx.doi.org/10.1007/s10895-008-0387-1] [PMID:  18523876]

[20]
Muthukutty B, Ganesamurthi J, Chen SM, Arumugam B, Chang FM, Wabaidur SM. Construction of novel binary metal oxides: Copper oxide–tin oxidenanoparticles regulated for selective and nanomolar levelelectrochemical detection of anti-psychotic drug. Electrochim Acta  2021; 386: 138482.
 [http://dx.doi.org/10.1016/j.electacta.2021.138482]

[21]
Brabec V, Kasparkova J. Ruthenium coordination compounds of biological and biomedical significance. DNA binding agents. Coord Chem Rev  2018; 376: 75-94.
 [http://dx.doi.org/10.1016/j.ccr.2018.07.012]

[22]
Zeng L, Gupta P, Chen Y. et al. The development of anticancer ruthenium (ii) complexes: From single molecule compounds to nano-materials. Chem Soc Rev  2017; 46(19): 5771-804.
 [http://dx.doi.org/10.1039/C7CS00195A] [PMID:  28654103]

[23]
Zhang X, Liu D, Lv F, Yu B, Shen Y, Cong H. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy. Colloids Surf B Biointerfaces  2019; 182(110373): 110373.
 [http://dx.doi.org/10.1016/j.colsurfb.2019.110373] [PMID:  31376689]

[24]
Osta MSC, Gonçalves YG, Borges BC. et al. Ruthenium (II) complex cis-[RuII(ŋ2-O2CC7H7O2)(dppm)2]PF6-hmxbato induces ROS-mediated apoptosis in lung tumor cells producing selective cytotoxicity. Sci Rep  2020; 10: 15410.
 [http://dx.doi.org/10.1038/s41598-020-72420-w] [PMID:  32958783]

[25]
Southam HM, Butler JA, Chapman JA, Poole RK. The microbiology of ruthenium complexes. Adv Microb Physiol  2017; 71: 1-96.

[26]
Małecka M, Skoczyńska A, Goodman DM, Hartinger CG, Budzisz E. Biological properties of ruthenium(II)/(III) complexes with flavo-noids as ligands. Coord Chem Rev  2021; 436(213849): 213849.
 [http://dx.doi.org/10.1016/j.ccr.2021.213849]

[27]
Leijen S, Burgers SA, Baas P. et al. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs  2015; 33(1): 201-14.
 [http://dx.doi.org/10.1007/s10637-014-0179-1] [PMID:  25344453]

[28]
Alessio E, Messori L. NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medici-nal inorganic chemistry. Molecules  2019; 24(10): 1995.
 [http://dx.doi.org/10.3390/molecules24101995] [PMID:  31137659]

[29]
Mabuza LP, Gamede MW, Maikoo S, Booysen IN, Ngubane PS, Khathi A. Effects of a ruthenium schiff base complex on glucose homeo-stasis in diet-induced pre-diabetic rats. Molecules  2018; 23(7): 1721.
 [http://dx.doi.org/10.3390/molecules23071721] [PMID:  30011905]

[30]
Jia Q, Liu Y, Yan F, Wang Q, Ma P. Predicting the activity of hydroxamic acid analogues. Mol Simul  2017; 43(13–16): 1026-33.
 [http://dx.doi.org/10.1080/08927022.2017.1353693]

[31]
Kaushal R. Sheetal. In vitro anticancer and antibacterial activities of octahedral ruthenium(III) complexes with hydroxamic acids. Synthe-sis and spectroscopic characterization. Russ J Gen Chem  2016; 86(2): 360-7.
 [http://dx.doi.org/10.1134/S1070363216020274]

[32]
Abdellatif KRA, Elshemy HAH, Salama SA, Omar HA. Synthesis, characterization and biological evaluation of novel 4′-fluoro-2′-hydroxy-chalcone derivatives as antioxidant, anti-inflammatory and analgesic agents. J Enzyme Inhib Med Chem  2015; 30(3): 484-91.
 [http://dx.doi.org/10.3109/14756366.2014.949255] [PMID:  25198887]

[33]
Shenvi S, Kumar K, Hatti KS, Rijesh K, Diwakar L, Reddy GC. Synthesis, anticancer and antioxidant activities of 2,4,5-trimethoxy chal-cones and analogues from asaronaldehyde: Structure-activity relationship. Eur J Med Chem  2013; 62: 435-42.
 [http://dx.doi.org/10.1016/j.ejmech.2013.01.018] [PMID:  23395966]

[34]
Avcı D, Altürk S, Sönmez F. et al. Three novel Cu(II), Cd(II) and Cr(III) complexes of 6−methylpyridine−2−carboxylic acid with thiocya-nate: Synthesis, crystal structures, DFT calculations, molecular docking and α-glucosidase inhibition studies. Tetrahedron  2018; 74(50): 7198-208.
 [http://dx.doi.org/10.1016/j.tet.2018.10.054]

[35]
Chi G, Wang L, Chen B. et al. Polyoxometalates: Study of inhibitory kinetics and mechanism against α-glucosidase. J Inorg Biochem  2019; 199(110784): 110784.
 [http://dx.doi.org/10.1016/j.jinorgbio.2019.110784] [PMID:  31351380]

[36]
Zheng JW, Ma L. Metal complexes of anthranilic acid derivatives: A new class of non-competitive α-glucosidase inhibitors. Chin Chem Lett  2016; 27(5): 627-30.
 [http://dx.doi.org/10.1016/j.cclet.2016.01.052]

[37]
Kotowaroo MI, Mahomoodally MF, Gurib-Fakim A, Subratty AH. Screening of traditional antidiabetic medicinal plants of mauritius for possible α-amylase inhibitory effects in vitro. Phytother Res  2006; 20(3): 228-31.
 [http://dx.doi.org/10.1002/ptr.1839] [PMID:  16521114]

[38]
Kaur M, Kaushal R. Synthesis and in-silico molecular modelling, DFT studies, antiradical and antihyperglycemic activity of novel vanadyl complexes based on chalcone derivatives. J Mol Struct  2022; 1252(132176): 132176.
 [http://dx.doi.org/10.1016/j.molstruc.2021.132176]

[39]
Acet Ö, Aksoy NH, Erdönmez D, Odabaşı M. Determination of some adsorption and kinetic parameters of α-amylase onto Cu+2-PHEMA beads embedded column. Artif Cells Nanomed Biotechnol  2018; 46: S538-45.
 [http://dx.doi.org/10.1080/21691401.2018.1501378]

[40]
Kalita D, Holm DG, LaBarbera DV, Petrash JM, Jayanty SS. Inhibition of α-glucosidase, α-amylase, and aldose reductase by potato poly-phenolic compounds. PLoS One  2018; 13(1): e0191025.
 [http://dx.doi.org/10.1371/journal.pone.0191025] [PMID:  29370193]

[41]
Taha M, Baharudin MS, Ismail NH. et al. Synthesis, α-amylase inhibitory potential and molecular docking study of indole derivatives. Bioorg Chem  2018; 80: 36-42.
 [http://dx.doi.org/10.1016/j.bioorg.2018.05.021] [PMID:  29864686]

[42]
Ammal PR, Prasad AR, Joseph A. Synthesis, characterization, in silico, and in vitro biological screening of coordination compounds with 1,2,4-triazine based biocompatible ligands and selected 3d-metal ions. Heliyon  2020; 6(10): e05144.
 [http://dx.doi.org/10.1016/j.heliyon.2020.e05144] [PMID:  33083609]

[43]
Functional Metabolism: Regulation and Adaptation. Storey KB, Ed. Hoboken, NJ, USA: John Wiley & Sons, Inc. 2004.

[44]
Md Abdur Rauf S, Arvidsson PI, Albericio F. et al. The effect of N-methylation of Amino acids (Ac-X-OMe) on solubility and confor-mation: A DFT study. Org Biomol Chem  2015; 13(39): 9993-10006.
 [http://dx.doi.org/10.1039/C5OB01565K] [PMID:  26289381]

[45]
Kurt M, Sas EB, Can M. et al. Synthesis and spectroscopic characterization on 4-(2,5-di-2-thienyl-1H-pyrrol-1-yl) benzoic acid: A DFT approach. Spectrochim Acta A Mol Biomol Spectrosc  2016; 152: 8-17.
 [http://dx.doi.org/10.1016/j.saa.2015.07.058] [PMID:  26186392]

[46]
Balan K, Ratha P, Prakash G, Viswanathamurthi P, Adisakwattana S, Palvannan T. Evaluation of in vitro α-amylase and α-glucosidase inhibitory potential of N2O2 schiff base Zn complex. Arab J Chem  2017; 10(5): 732-8.
 [http://dx.doi.org/10.1016/j.arabjc.2014.07.002]

[47]
Wang X, Ling N, Zhang YW, Wang X, Yang HX. Synthesis, structure, antidiabetic and antioxidant properties of a new Co(II) complex with a flexible tripodal ligand. Inorg Chem Commun  2019; 110(107585): 107585.
 [http://dx.doi.org/10.1016/j.inoche.2019.107585]

[48]
Sneha Jose E, Philip JE, Shanty AA, Kurup MRP, Mohanan PV. Novel class of mononuclear 2-methoxy-4-chromanones ligated Cu (II), Zn (II), Ni (II) complexes: Synthesis, characterisation and biological studies. Inorganica Chim Acta  2018; 478: 155-65.
 [http://dx.doi.org/10.1016/j.ica.2018.03.023]

[49]
Lipkind GM, Fozzard HA. Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol  2005; 68(6): 1611-22.
 [http://dx.doi.org/10.1124/mol.105.014803] [PMID:  16174788]

[50]
Naaz S, Laskar RA, Rahaman SK. et al. Supramolecular assembly of a terpyridyl based binuclear Cu(II) complex and its DNA docking study. Supramol Chem 2022. [ePub ahead of print] http://dx.doi.org/10.1080/10610278.2022.2057228

[51]
Bhowmick S, AlFaris NA. Zaidan ALTamimi J, et al. Identification of bio-active food compounds as potential SARS-CoV-2 PLpro inhibi-tors-modulators via negative image-based screening and computational simulations. Comput Biol Med  2022; 145: 105474.
 [http://dx.doi.org/10.1016/j.compbiomed.2022.105474] [PMID:  35395517]

Rights & Permissions Print Cite

Article Metrics

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1573408018666220825152849	Print ISSN 1573-4080
Publisher Name Bentham Science Publisher	Online ISSN 1875-6662

Current Enzyme Inhibition

Antidiabetic Potential of Ruthenium(III) Hydroxamate Complexes: Spectrophotometric Investigations

Abstract Play Pause

Graphical Abstract

Related Books

Abstract